| DIRECT COMPETITOR COMPARISON | |
| EBS | CRXL | Pvt1 | HGSI | Industry | | Market Cap: | 408.07M | N/A | N/A | 4.55B | 97.36M | | Employees: | 587 | N/A | 251 | 880 | 65 | | Qtrly Rev Growth (yoy): | -23.50% | N/A | N/A | 61.30% | 19.70% | | Revenue (ttm): | 216.73M | N/A | 4.20M1 | 235.70M | 14.01M | | Gross Margin (ttm): | 48.84% | N/A | N/A | 10.36% | 65.68% | | EBITDA (ttm): | 45.09M | N/A | N/A | -8.22M | -12.25M | | Oper Margins (ttm): | 18.45% | N/A | N/A | -12.73% | -137.11% | | Net Income (ttm): | 28.36M | N/A | N/A | -22.51M | N/A | | EPS (ttm): | 0.905 | N/A | N/A | -0.160 | -0.31 | | P/E (ttm): | 14.64 | N/A | N/A | N/A | 17.26 | | PEG (5 yr expected): | N/A | N/A | N/A | 186.73 | 1.28 | | P/S (ttm): | 2.05 | N/A | N/A | 19.27 | 9.82 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 55.93 | -0.97% | 56.61B | 12.20 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 48.06 | -0.50% | 13.90B | 16.08 | | Genzyme Corp. | GENZ | 49.42 | -0.60% | 13.12B | 28.18 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.12 | -1.07% | 41.50B | 17.83 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.87 | -1.48% | 8.89B | 1017.76 | | Teva Pharmaceutical Industries Limited | TEVA | 52.44 | -1.52% | 46.20B | 47.98 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.77 | -0.42% | 4.01B | 19.47 | | King Pharmaceuticals Inc. | KG | 11.30 | -1.91% | 2.81B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.14 | -0.22% | 5.54B | 111.29 | | Pfizer Inc. | PFE | 17.76 | -1.66% | 143.31B | 14.75 | | Johnson & Johnson | JNJ | 64.25 | -0.19% | 177.27B | 14.03 | | GlaxoSmithKline plc | GSK | 42.05 | -1.38% | 106.60B | 13.26 | | Sanofi-Aventis | SNY | 38.73 | -0.13% | 101.13B | N/A | | Novartis AG | NVS | 55.33 | -0.31% | 125.67B | 16.57 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 40.80 | -1.35% | N/A | N/A | | AstraZeneca plc | AZN | 45.70 | -0.93% | 66.27B | 9.18 | | Abbott Laboratories | ABT | 53.24 | -0.78% | 82.35B | 14.42 | | Bristol-Myers Squibb Co. | BMY | 24.90 | -1.50% | 49.33B | 12.88 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | HGSI | | Human Genome Sciences raises $456.3M in stock sale
Tue 1:07pm -
AP | | • | HGSI | | Human Genome Sciences Announces Closing of Public Offering of Common Stock
Tue 11:47am -
Business Wire | | • | HGSI | | HUMAN GENOME SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Tue 9:07am -
EDGAR Online | | • | HGSI | | [$$] Small-Caps, Breadth Hold Their Ground
Mon 8:00am -
at RealMoney by TheStreet.com | | • | HGSI | | One Bet You're Sure to Lose
Thu, Dec 3 -
at Motley Fool | | • | CRXL | | Vaccines on horizon for AIDS, Alzheimer's, herpes
Wed, Nov 18 -
AP | | • | CRXL | | Vaccines on horizon for AIDS, Alzheimer's, herpes
Tue, Nov 17 -
AP | | • | CRXL | | Crucell launches global brand to reflect and reinforce its leading position in healthcare innovation
Mon, Nov 16 -
Marketwire | | • | CRXL | | The Complete List of Dutch ADR Stocks
Wed, Nov 11 -
at Seeking Alpha | | • | CRXL | | TapImmune Signs License Agreement With Crucell N.V.
Thu, Nov 5 -
GlobeNewswire | | • | CRXL | | Crucell N.V. upgraded by UBS
Thu, Nov 5 -
Briefing.com | | | All Headlines for these symbols... |
|
|
|
1.00% Nasdaq 
Competitors
